Cargando…

Continuous renal replacement therapy using a cellulose triacetate hemofilter for severe coronavirus disease

BACKGROUND: In patients with severe coronavirus disease (COVID-19), the use of acrylonitrile hemofilters can reduce cytokine concentrations. However, acrylonitrile hemofilters can easily coagulate, and the effect of hemofilters on improvement in patient prognosis remains unclear. Therefore, we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Kanako, Inoue, Hiroyuki, Kishimoto, Masumi, Nakayama, Ryuichi, Kasai, Takehiko, Bunya, Naofumi, Harada, Keisuke, Uemura, Shuji, Narimatsu, Eichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444108/
https://www.ncbi.nlm.nih.gov/pubmed/36093318
http://dx.doi.org/10.1186/s41100-022-00436-1
_version_ 1784783143045169152
author Takahashi, Kanako
Inoue, Hiroyuki
Kishimoto, Masumi
Nakayama, Ryuichi
Kasai, Takehiko
Bunya, Naofumi
Harada, Keisuke
Uemura, Shuji
Narimatsu, Eichi
author_facet Takahashi, Kanako
Inoue, Hiroyuki
Kishimoto, Masumi
Nakayama, Ryuichi
Kasai, Takehiko
Bunya, Naofumi
Harada, Keisuke
Uemura, Shuji
Narimatsu, Eichi
author_sort Takahashi, Kanako
collection PubMed
description BACKGROUND: In patients with severe coronavirus disease (COVID-19), the use of acrylonitrile hemofilters can reduce cytokine concentrations. However, acrylonitrile hemofilters can easily coagulate, and the effect of hemofilters on improvement in patient prognosis remains unclear. Therefore, we aimed to investigate the changes in serum cytokine concentrations, alleviation of organ damage, and improvement in patient prognosis with continuous renal replacement therapy (CRRT) using a cellulose triacetate (CTA) filter with excellent anticoagulation property in patients with severe COVID-19. METHODS: This was a retrospective, single-center study conducted by the Advanced Critical Care Center in Sapporo Medical University Hospital, Japan. Seven patients with severe COVID-19 between March 01 and June 30, 2020, were included. The patients were under mechanical ventilation and received continuous blood purification therapy with a CTA filter. We summarized the CRRT status and patient prognosis and measured their serum cytokine (interleukin [IL]-1β, IL-4, IL-6, IL-8, IL-10, tumor necrosis factor-α, and interferon-γ) and serum marker levels, before and after CRRT. In addition, we evaluated the changes in their respiratory status, hemodynamics, and organ dysfunction scores. The average age of the patients was 61.5 years, and five patients were male. Extracorporeal membrane oxygenation was used in five patients. The treatment outcome included three deaths. RESULTS: The median CRRT duration was 7 days. The hemofilter was replaced once a day. After CRRT, the IL-6 concentration decreased from 393 to 85 pg/mL (p = 0.016), the Krebs von den Lungen-6 concentration decreased from 554 to 350 U/mL, and the PaO(2)/FiO(2) ratio increased significantly from 90 to 248, and therefore, oxygenation improved. In addition, the norepinephrine dose and lactate level decreased, and the circulation tended to improve; however, the renal function and Sequential Organ Failure Assessment score did not change. CONCLUSIONS: The serum IL-6 level decreased, and the respiratory status improved upon CRRT using a CTA filter in patients with severe COVID-19.
format Online
Article
Text
id pubmed-9444108
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94441082022-09-06 Continuous renal replacement therapy using a cellulose triacetate hemofilter for severe coronavirus disease Takahashi, Kanako Inoue, Hiroyuki Kishimoto, Masumi Nakayama, Ryuichi Kasai, Takehiko Bunya, Naofumi Harada, Keisuke Uemura, Shuji Narimatsu, Eichi Ren Replace Ther Case Report BACKGROUND: In patients with severe coronavirus disease (COVID-19), the use of acrylonitrile hemofilters can reduce cytokine concentrations. However, acrylonitrile hemofilters can easily coagulate, and the effect of hemofilters on improvement in patient prognosis remains unclear. Therefore, we aimed to investigate the changes in serum cytokine concentrations, alleviation of organ damage, and improvement in patient prognosis with continuous renal replacement therapy (CRRT) using a cellulose triacetate (CTA) filter with excellent anticoagulation property in patients with severe COVID-19. METHODS: This was a retrospective, single-center study conducted by the Advanced Critical Care Center in Sapporo Medical University Hospital, Japan. Seven patients with severe COVID-19 between March 01 and June 30, 2020, were included. The patients were under mechanical ventilation and received continuous blood purification therapy with a CTA filter. We summarized the CRRT status and patient prognosis and measured their serum cytokine (interleukin [IL]-1β, IL-4, IL-6, IL-8, IL-10, tumor necrosis factor-α, and interferon-γ) and serum marker levels, before and after CRRT. In addition, we evaluated the changes in their respiratory status, hemodynamics, and organ dysfunction scores. The average age of the patients was 61.5 years, and five patients were male. Extracorporeal membrane oxygenation was used in five patients. The treatment outcome included three deaths. RESULTS: The median CRRT duration was 7 days. The hemofilter was replaced once a day. After CRRT, the IL-6 concentration decreased from 393 to 85 pg/mL (p = 0.016), the Krebs von den Lungen-6 concentration decreased from 554 to 350 U/mL, and the PaO(2)/FiO(2) ratio increased significantly from 90 to 248, and therefore, oxygenation improved. In addition, the norepinephrine dose and lactate level decreased, and the circulation tended to improve; however, the renal function and Sequential Organ Failure Assessment score did not change. CONCLUSIONS: The serum IL-6 level decreased, and the respiratory status improved upon CRRT using a CTA filter in patients with severe COVID-19. BioMed Central 2022-09-05 2022 /pmc/articles/PMC9444108/ /pubmed/36093318 http://dx.doi.org/10.1186/s41100-022-00436-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Takahashi, Kanako
Inoue, Hiroyuki
Kishimoto, Masumi
Nakayama, Ryuichi
Kasai, Takehiko
Bunya, Naofumi
Harada, Keisuke
Uemura, Shuji
Narimatsu, Eichi
Continuous renal replacement therapy using a cellulose triacetate hemofilter for severe coronavirus disease
title Continuous renal replacement therapy using a cellulose triacetate hemofilter for severe coronavirus disease
title_full Continuous renal replacement therapy using a cellulose triacetate hemofilter for severe coronavirus disease
title_fullStr Continuous renal replacement therapy using a cellulose triacetate hemofilter for severe coronavirus disease
title_full_unstemmed Continuous renal replacement therapy using a cellulose triacetate hemofilter for severe coronavirus disease
title_short Continuous renal replacement therapy using a cellulose triacetate hemofilter for severe coronavirus disease
title_sort continuous renal replacement therapy using a cellulose triacetate hemofilter for severe coronavirus disease
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444108/
https://www.ncbi.nlm.nih.gov/pubmed/36093318
http://dx.doi.org/10.1186/s41100-022-00436-1
work_keys_str_mv AT takahashikanako continuousrenalreplacementtherapyusingacellulosetriacetatehemofilterforseverecoronavirusdisease
AT inouehiroyuki continuousrenalreplacementtherapyusingacellulosetriacetatehemofilterforseverecoronavirusdisease
AT kishimotomasumi continuousrenalreplacementtherapyusingacellulosetriacetatehemofilterforseverecoronavirusdisease
AT nakayamaryuichi continuousrenalreplacementtherapyusingacellulosetriacetatehemofilterforseverecoronavirusdisease
AT kasaitakehiko continuousrenalreplacementtherapyusingacellulosetriacetatehemofilterforseverecoronavirusdisease
AT bunyanaofumi continuousrenalreplacementtherapyusingacellulosetriacetatehemofilterforseverecoronavirusdisease
AT haradakeisuke continuousrenalreplacementtherapyusingacellulosetriacetatehemofilterforseverecoronavirusdisease
AT uemurashuji continuousrenalreplacementtherapyusingacellulosetriacetatehemofilterforseverecoronavirusdisease
AT narimatsueichi continuousrenalreplacementtherapyusingacellulosetriacetatehemofilterforseverecoronavirusdisease